– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, cardiovascular disease, and Neuroscience, each representing a blockbuster opportunity – – Announces TRITON Phase 3 program for next-generation TTR silencer nucresiran in ATTR-CM and hATTR-PN, targeting durable franchise leadership – – Provides details about Phase 3 cardiovascular outcomes trial for zilebesiran, poised to transform the treatment of hypertension in patients with high CV risk – …

Verona Pharma Conference Announcements Verona Pharma (VRNA) announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45th Annual Health Care Conference Date: Monday, March 3, 2025: Time: 11:10 a.m. ET / 4:10 p.m. GMT Location: Boston, MA Leerink Partners 2025 Global Healthcare . . . This content is for paid subscribers. Please click here to subscribe or …

Gilead Sciences On February 20, 2025, Gilead Sciences (GILD) announced that the European Commission (EC) granted conditional marketing authorization to seladelpar in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults who have inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Now approved, Seladelpar (an orphan-designated . . . This content is for …

Alnylam Pharmaceuticals Questions & Answers Q: Why has Alnylam Pharmaceuticals’ stock plummeted recently? A: We do not forget that Alnylam Pharmaceuticals (ALNY) is the leading RNAi Therapeutics. Keeping this in mind is important as RNAi therapeutic enables Alnylam to develop treatments together with future novel products created through gene editing, gene therapies, AI and other future technologies.  In . . . This content is for …

 What About GRAIL Inc? GRAIL Inc (GRAL) is a healthcare company on a mission to detect cancers early so they can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, state-of-the-art machine learning, software, and automation to detect and identify multiple deadly . . . This content is for paid subscribers. Please …

Sanofi A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi (SNY) and Johnson & Johnson’s (

Anavex Life Sciences Below Today is the earnings report day for Anavex Life Sciences (AVXL) and Biogen (

Boehringer Ingelheim Today, Boehringer Ingelheim, a private Company announced that the FIBRONEER™-ILD trial met its primary endpoint, which was the absolute change from baseline in FVC (mL) at week 52 versus placebo. FVC is a measure of lung function.  Initial data readouts of the FIBRONEER™-trials support a generally consistent safety and tolerability profile when compared to the Phase II IPF study, with overall adverse events comparable to …

Eledon Pharmaceuticals The patient was treated in the procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, and was recently released from the hospital.  Today,  February 07, 2025, Eledon Pharmaceuticals (ELDN) announced that tegoprubart, its investigational anti-CD40L antibody, was used as a key component of the immunosuppression therapy regimen in a patient who recently received . . . This content is …

Supernus Pharmaceuticals Supernus Pharmaceuticals (SUPN) - a biopharmaceutical company focused on developing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults . . . This content is for …

Halozyme Therapeutics Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorization for a subcutaneous (SC) formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for . . . This content is for paid subscribers. Please click here …

Vertex Pharmaceuticals Yesterday, January 30, 2025, Vertex Pharmaceuticals (VRTX) announced FDA approval of journavx™(suzetrigine), a First-in-Class treatment for adults with moderate-to-severe acute pain. Today, Vertex Announced the CASGEVY® Reimbursement Agreement for treating Sickle Cell Disease in England. We start with the Approval of the JOURNAVX™ News Yesterday, after the stock market closed, Vertex Pharmaceuticals announced that the  U . . . This content is for paid …

AstraZeneca FDA Approval On January 27, 2025, Daiichi Sankyo (TSE: 4568) and AstraZeneca (AZN) product ENHERTU® (fam-trastuzumab deruxtecan-nxki) was approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low or HER2 ultralow breast cancer, as determined by an FDA-approved test, that has progressed on one . . . This content is for paid subscribers. Please click here …

Akero Therapeutics Full Press Release Following our shortened report earlier today, this posting is from the Company’s information and its press release. The news demonstrated statistically significant compensated cirrhosis (F4) reversal due to MASH by Both Completer and ITT Analyses at Week 96 in Phase 2b SYMMETRY Study. Akero Therapeutics (AKRO), released preliminary topline week 96 results from SYMMETRY . . . This content is …

Akero Therapeutics Waiting to hear the news from Akero Therapeutics in treating NASH, the company reported Preliminary Topline Results showing statistically significant reversal of compensated Cirrhosis (F4) due to Mash-by both completer and ITT analyses- at week 96 in Phase 2b SYMMETRY Study. Indeed, Akero Therapeutics (

Vera Therapeutics in the Market Today Today, many investors in the biotechnology market caused a selloff of Vera Therapeutics (VERA) following its announcement of an exclusive license agreement with Stanford University to acquire a next generation fusion protein targeting BAFF and APRIL, known as VT-109. VT-109 has wide therapeutic potential across the spectrum of B cell mediated diseases. What Vera Therapeutics . . . This …

Compugen  January 8, 2025, Compugen (CGEN), announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead. Compugen is responsible for running the Phase 1 trial. This Phase 1 multi-center dose escalation and dose expansion trial will evaluate the safety, tolerability . . . This content is for …

Halozyme Therapeutics Today, January 8, 2025 /PRNewswire/ - Halozyme Therapeutics, Inc. (HALO) provided a financial update, reiterating full year 2024 financial guidance and raising full year 2025 and multi-year financial guidance. The Company has also announced that. it has recently entered into . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Verona Pharma Today, January 7, 2024 Verona Pharma (VRNA) announced preliminary unaudited net product sales for the fourth quarter and full year ended December 31, 2024, and provides a corporate update. Let’s read what the Company’s President stated: David Zaccardelli, Pharm. D., President and Chief Executive Officer said,“2024 was another transformational year for Verona with the approval and US . . . This content is …

Verastem Oncology in the NEWS On December 30, 2024, Verastem Oncology (VSTM) announced that the U.S. FDA has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib. The drug is in combination with defactinib, an oral FAK inhibitor, for the treatment of adult patients with recurrent low-grade serous ovarian cancer (LGSOC . . . This content is for paid …